MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Cisplatin (Platinol ®)

Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases.

Clinical Lung Cancer 2018 November 29 [Link] McGehee E, Gerber DE, Reisch J, Dowell JE Abstract Primary pericardial mesothelioma (PPM) is a rare cancer for which there is no consensus on treatment. We evaluated and summarized a large contemporary population of published PPM cases to characterize risk factors, treatment patterns, and clinical outcomes. Using Ovid […]

Comments Off on Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases.

The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma.

Journal of Clinical Pharmacy and Therapeutics 2018 December 2018 [Link] Mense ES, Smit AAJ, Crul M, Franssen EJF Abstract WHAT IS KNOWN AND OBJECTIVE: The use of cisplatin in the treatment of lung carcinoma is limited by nephrotoxicity. The aim of this study was to determine whether the incidence of nephrotoxicity in patients with lung […]

Comments Off on The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma.

A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205).

Translational Lung Cancer Research 2018 October [Link] Raskin J, Surmont V, Cornelissen R, Baas P, van Schil PEY, van Meerbeeck JP Abstract Radical multimodality treatment for malignant pleural mesothelioma (MPM) is controversial, with intense debate (but lack of data) about which surgical procedure to perform [extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD)], if any. In order […]

Comments Off on A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205).

Real-life treatment practice for malignant pleural mesothelioma in Belgium.

Lung Cancer 2018 November [Link] Rosskamp M, Macq G, Nackaerts K, Praet M, Van Eycken L, Van Meerbeeck JP, De Schutter H Abstract OBJECTIVES: Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer, for which treatment is often limited to palliative combination chemotherapy. Multimodality-therapy, including radical surgery, is largely restricted to clinical trials, leaving […]

Comments Off on Real-life treatment practice for malignant pleural mesothelioma in Belgium.

Multimodality treatment of malignant pleural mesothelioma.

F1000Research 2018 October 22 [Link] Berzenji L, Van Schil P Abstract Malignant pleural mesothelioma (MPM) is a rare disease of the pleura and is largely related to asbestos exposure. Despite recent advancements in technologies and a greater understanding of the disease, the prognosis of MPM remains poor; the median overall survival rate is about 6 […]

Comments Off on Multimodality treatment of malignant pleural mesothelioma.

Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.

Medicine 2018 November [Link] Du Z, Yu Y, Wu D, Zhang G, Wang Y, He L, Meng R Abstract RATIONALE: Malignant Pleural Mesothelioma (MPM) is rare cancer and has a poor prognosis with resistance to chemotherapy or radiotherapy. Until now there is no standard third-line treatment for patients who have failed second-line therapy. PATIENT CONCERNS: […]

Comments Off on Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report.

BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.

PloS One 2018 August 29 [Link] Rath EM, Cheng YY, Pinese M, Sarun KH, Hudson AL, Weir C, Wang YD, Håkansson AP, Howell VM, Liu GJ, Reid G, Knott RB, Duff Abstract Malignant pleural mesothelioma is an aggressive cancer with poor prognosis. Here we have investigated in vitro efficacy of BAMLET and BLAGLET complexes (anti-cancer […]

Comments Off on BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.

Current treatments and trials in malignant pleural mesothelioma.

The Clinical Respiratory Journal 2018 July 12 [Link] Bibby AC, Maskell NA Abstract OBJECTIVES: This article aims to review the evidence from recent clinical trials in mesothelioma, and to provide an overview of relevant clinical trials that are currently in progress. DATA SOURCE: Ovid MEDLINE, 1946 to present. STUDY SELECTION: Clinical trials of therapeutic interventions […]

Comments Off on Current treatments and trials in malignant pleural mesothelioma.

Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma.

BMC Cancer 2018 August 15 [Link] Kim MC, Hwang SH, Kim NY, Lee HS, Ji S, Yang Y, Kim Y Abstract BACKGROUND: Hypoxia is a hallmark of the solid tumor microenvironment and is associated with poor outcomes in cancer patients. The present study was performed to investigate mechanisms underlying the hypoxia-induced phenotypic changes using human […]

Comments Off on Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma.

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.

Journal of Oncology 2018 July 17 Link] Walter RFH, Werner R, Wessolly M, Mairinger E, Borchert S, Schmeller J, Kollmeier J, Mairinger T, Hager T, Bankfalvi A, Christoph DC, Eberhardt WEE, Plönes T, Aigner C, Schmid KW, Wohlschlaeger J, Mairinger FD Abstract Previously, our group demonstrated that nuclear expression of E3 ubiquitin ligase (MDM2) in […]

Comments Off on Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.